The purpose of the "Right-to-try" law is to authorize the use of unapproved medical products by patients diagnosed with a terminal illness in accordance with State law, and for other purposes. This bill was signed into law on May 30, 2018 (Citation).

The unapproved medical products have completed Phase I of clinical trials, which means that they have been tested on a limited number of healthy individuals (20-80). However, these medical products have not been tested on individuals with the targeted disease, nor have they been compared to placebo or positive controls (older drugs that have been approved by the FDA) (Hart, C. L., & Ksir, C. (2013)).

Below are articles that you may find interesting in relation to this topic:

**Any thoughts, comments, questions, etc. are welcomed in the Unit 2 Discussion Board. Just start your own thread!

[You will not be responsible for any of the material covered on this page beyond what was discussed in other modules.]